Defining Benchmark Outcomes for Distal Pancreatectomy: Results of a French Multicentric Study.
(1)
,
(2)
,
(3)
,
(4)
,
(5, 6)
,
(7)
,
(8)
,
(9, 10, 11)
,
(12, 13)
,
(14)
,
(15, 2)
,
(16, 17)
,
(16, 17)
,
(6)
,
,
(18)
,
(19, 18)
,
(20)
,
(21)
,
(17)
,
(22)
,
(23)
,
(24, 25)
,
(26)
,
,
(27)
,
(28, 29)
,
(30)
,
(31)
,
(32)
,
(33, 34)
,
(35, 36)
,
(1)
,
(1)
,
(1)
,
(1)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
Piettro Addeo
- Fonction : Auteur
Ecoline Tribillon
- Fonction : Auteur
Jean-Marc Regimbeau
- Fonction : Auteur
- PersonId : 1078724
- ORCID : 0000-0001-7631-9112
- IdRef : 076392481
Résumé
OBJECTIVE: Defining robust and standardized outcome references for distal pancreatectomy (DP) by using Benchmark analysis. BACKGROUND: Outcomes after DP are recorded in medium or small-sized studies without standardized analysis. Therefore, the best results remain uncertain. METHODS: This multicenter study included all patients undergoing DP for resectable benign or malignant tumors in 21 French expert centers in pancreas surgery from 2014 to 2018. A low-risk cohort defined by no significant comorbidities was analyzed to establish 18 outcome benchmarks for DP. These values were tested in high-risk, minimally invasive and benign tumor cohorts. RESULTS: 1188 patients were identified and 749 low-risk patients were screened to establish Benchmark cut-offs. Therefore, Benchmark rate for mini-invasive approach was ≥q36.8%. Benchmark cut-offs for postoperative mortality, major morbidity grade ≥q3a and clinically significant pancreatic fistula rates were 0%, ≤q27% and ≤q28%, respectively. The benchmark rate for readmission was ≤q 16%. For patients with pancreatic adenocarcinoma, cut-offs were ≥q75%, ≥q69.5% and ≥q66% for free resection margins (R0), 1-year disease free-survival and 3-year overall survival, respectively. The rate of mini-invasive approach in high-risk cohort was lower than the Benchmark cut-off (34.1% vs. ≥q36.8%). All Benchmark cut-offs were respected for benign tumor group. The proportion of benchmark cases was correlated to outcomes of DP. Centers with a majority of low-risk patients had worse results than those operating complex cases. CONCLUSION: This large-scale study is the first benchmark analysis of DP outcomes and provides robust and standardized data. This may allow for comparisons between surgeons, centers, studies, and surgical techniques.